Antonio Palumbo, MD from the University of Turin, Turin, Italy discusses the place of daratumumab in the current treatment landscape of multiple myeloma (MM). According to Dr Palumbo, daratumumab will change the treatment paradigm and will be combined to bortezomib and dexamethasone or lenalidomide and dexamethasone.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
EHA 2016: How daratumumab will change the treatment of multiple myeloma
